Genmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Genmab A/S (NASDAQ:GMAB) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $41.33.

GMAB has been the subject of a number of research reports. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its stake in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after purchasing an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC grew its position in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares in the last quarter. Finally, Grandfield & Dodd LLC grew its position in Genmab A/S by 4.2% during the fourth quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company’s stock worth $704,000 after buying an additional 1,370 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Trading Down 1.2 %

GMAB stock opened at $19.90 on Friday. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $30.50. The stock has a 50-day moving average price of $20.89 and a 200-day moving average price of $21.88. The firm has a market cap of $13.17 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.